V. Alexander

发表

Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results1

J. Witztum, S. Tsimikas, Yun-Seok Choi, 2016, Journal of Lipid Research.

Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers

E. Hurh, R. Geary, S. Tsimikas, 2020, Nucleic acid therapeutics.

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

D. Gaudet, R. Hegele, E. Steinhagen-Thiessen, 2021, The lancet. Diabetes & endocrinology.

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

D. Gaudet, J. Kastelein, D. Brisson, 2015, The New England journal of medicine.

Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study.

A. Mertens, A. Garg, E. Hurh, 2022, Journal of clinical lipidology.

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.

D. Gaudet, S. Freedman, D. Blom, 2019, The New England journal of medicine.

Apolipoprotein C-III Inhibition with Volanesorsen in Patients with Hypertriglyceridemia (COMPASS): a Randomized, Double-Blind, Placebo-controlled Trial

D. Gaudet, E. Steinhagen-Thiessen, I. Gouni-Berthold, 2017, Atherosclerosis Supplements.

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Richard G. Lee, S. Crooke, M. Graham, 2013, Circulation research.

ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance[S]

Christian M. Metallo, R. Krauss, C. Benner, 2019, Journal of Lipid Research.

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels

J. Witztum, E. Hurh, R. Geary, 2019, European heart journal.

Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III

Xiaoke Yin, M. Mayr, S. Kiechl, 2017, Journal of the American College of Cardiology.

Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOCIII.

M. Mayr, S. Kiechl, P. Willeit, 2017 .

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Richard G. Lee, S. Bhanot, M. Graham, 2016, Diabetes Care.

Targeting APOC3 in the familial chylomicronemia syndrome.

D. Gaudet, D. Brisson, K. Tremblay, 2014, The New England journal of medicine.

Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.

D. Gaudet, R. Hegele, E. Bruckert, 2017, Journal of clinical lipidology.

Inhibition of Prekallikrein for Hereditary Angioedema.

J. Bernstein, W. Lumry, B. Baker, 2022, The New England journal of medicine.

Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.

R. Santos, D. Blom, L. Hemphill, 2017, Journal of clinical lipidology.

Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia.

D. Gaudet, J. Tardif, C. Ballantyne, 2022, Journal of clinical lipidology.

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

D. Gaudet, J. Tardif, C. Ballantyne, 2022, European heart journal.

Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Richard G. Lee, S. Bhanot, M. Graham, 2016 .

Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles

D. Gaudet, R. Hegele, E. Bruckert, 2019, Journal of the Endocrine Society.

Treatment with Volanesorsen (VLN) Reduced Triglycerides and Pancreatitis in Patients with FCS and sHTG vs Placebo: Results of the APPROACH and COMPASS †

D. Gaudet, E. Bruckert, E. Stroes, 2018 .

INHIBITION OF APOLIPOPROTEIN C-III WITH GALNAC CONJUGATED ANTISENSE DRUG POTENTLY LOWERS FASTING SERUM APOLIPOPROTEIN C-III AND TRIGLYCERIDE LEVELS IN HEALTHY VOLUNTEERS WITH ELEVATED TRIGLYCERIDES

J. Witztum, E. Hurh, R. Geary, 2018 .

Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.

D. Gaudet, R. Hegele, E. Bruckert, 2017, Journal of clinical lipidology.

Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial.

D. Gaudet, M. Arca, E. Stroes, 2023, Journal of clinical lipidology.

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.

D. Gaudet, M. Arca, S. Tsimikas, 2019, The New England journal of medicine.

Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.

R. Santos, D. Blom, L. Hemphill, 2017, Journal of clinical lipidology.

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Richard G. Lee, S. Crooke, M. Graham, 2013, Circulation research.

APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia.

S. Tsimikas, S. Xia, E. Karwatowska-Prokopczuk, 2023, Journal of clinical lipidology.

An Antisense Inhibitor of Apolipoprotein C-III Substantially Decreases Fasting Apolipoprotein C-III and Triglyceride Levels in LPL Deficiency

D. Gaudet, K. Tremblay, R. Geary, 2014 .

Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema.

E. Stroes, M. Levi, B. Baker, 2020, The New England journal of medicine.